Revenue: As of FY2025 Q1, the actual value is USD 15.91 M.EPS: As of FY2025 Q1, the actual value is USD 0.06.<h3>Segment Revenue</h3><ul><li>Income from Purchased Receivables under the EIR Method: $6.07 million for the three months ended March 31, 2025, compared to $0 for the same period in 2024.</li><li>Income from Purchased Receivables under the Cost Recovery Method: $5.525 million for the three months ended March 31, 2025, compared to $0 for the same period in 2024.</li><li>Revenue from Contracts with Customers: $4 million for the three months ended March 31, 2025, compared to $1 million for the same period in 2024.</li><li>Revenue Recognized under Units-of-Revenue Method: $317,000 for the three months ended March 31, 2025, compared to $490,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $2.367 million for the three months ended March 31, 2025, compared to a net loss of $8.595 million for the same period in 2024.</li><li>Operating Expenses: Total operating expenses were $9.983 million for the three months ended March 31, 2025, compared to $8.494 million for the same period in 2024.</li><li>Interest Expense: $3.467 million for the three months ended March 31, 2025, compared to $3.551 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: $2.198 million for the three months ended March 31, 2025, compared to net cash used in operating activities of $4.947 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: $6.693 million for the three months ended March 31, 2025, compared to $7.246 million for the same period in 2024.</li><li>Net Cash Used in Financing Activities: $6.894 million for the three months ended March 31, 2025, compared to $4.956 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Exarafenib Milestone Asset: Valued at $3.307 million as of March 31, 2025.</li><li>Investment in Equity Securities: $2.382 million as of March 31, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company expects most of its future income and revenue to be based on payments received for milestones and royalties associated with its assets, as well as periodic recognition of income under the EIR method.</li><li>Non-Core Business: The company completed the sale of all five pipeline assets acquired in the Kinnate acquisition, eligible to receive up to $270 million in upfront and milestone payments, as well as future royalty payments.</li></ul>

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 10-Q: FY2025 Q1 Revenue: USD 15.91 M